Infections, Papillomavirus Clinical Trial
Official title:
A Multicentre Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine (GSK1674330A) in Healthy Female Subjects Aged 18-25 Years.
Verified date | May 2017 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Infection with human papillomavirus (HPV) has been clearly established as the central cause
of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of
the uterus or womb). This infection may go away by itself, but if it does not go away (this
is called persistent infection), it can lead in women over a long period of time to cancer
of the cervix. GlaxoSmithKline Biologicals has developed a HPV vaccine against the oncogenic
types HPV-16 and HPV-18 formulated with the AS04 adjuvant (control vaccine) and is also
evaluating novel HPV vaccines formulations. This study will evaluate a novel GSK
Biologicals' HPV vaccine (GSK1674330A) in terms of safety and immunogenicity compared to the
control vaccine. There will be different levels of blinding in the study.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
2007.
Status | Completed |
Enrollment | 540 |
Est. completion date | October 13, 2008 |
Est. primary completion date | June 30, 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 25 Years |
Eligibility |
Inclusion Criteria: - A woman whom the investigator believes can and will comply with the requirements of the protocol. - A woman between, and including, 18 and 25 years of age at the time of the first vaccination. - Written informed consent must be obtained from the subject prior to enrolment. - Healthy subjects as established by medical history and clinical examination before entering into the study. - Subject must be of non-childbearing potential, or if of child bearing potential, she must have a negative pregnancy test and she must be using adequate contraceptive precautions for 30 days prior to the first vaccination and must agree to continue such precautions for two months after completion of the vaccination series. - Subject who has had no more than 6 lifetime sexual partners prior to enrolment. Exclusion Criteria: - Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to six months after last dose of vaccine. - Concurrently participating in another clinical study, at any time during the study period (up to six months after last dose of vaccine), in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). - Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose or planned during the study period up to one month after last dose of vaccine. - Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after (i.e. days 0-29) the first dose of study vaccine. Planned administration/administration of routine vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the subject is outside of specified window. - Pregnant or breastfeeding. Women must be at least 3 months post-pregnancy and not breastfeeding to enter the study. - A woman planning to become pregnant or planning to discontinue contraceptive precautions during the study period, up to two months after the last vaccine dose. - Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period. - Previous administration of components of the investigational vaccine - Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccines. - Hypersensitivity to latex. - Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality, as determined by previous physical examination or laboratory tests. - Cancer or autoimmune disease under treatment. - History of allergic disease, suspected allergy or reactions likely to be exacerbated by any component of the study vaccines. - History of having had colposcopy or has planned a colposcopy to evaluate an abnormal cervical cytology test. - Received immunoglobulins and/or blood product within 3 months preceding enrolment or planned administration during the study period up to one month after the last dose of vaccine. Enrolment will be deferred until the subject is outside of specified window. - Acute disease at the time of enrolment. - Heavy bleeding (menstruation or other) or heavy vaginal discharge in which a cervical sample cannot be collected. Enrolment will be deferred until condition is resolved according to investigators medical judgement. |
Country | Name | City | State |
---|---|---|---|
Belgium | GSK Investigational Site | Bruxelles | |
Belgium | GSK Investigational Site | Gent | |
Belgium | GSK Investigational Site | Wilrijk |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence, intensity and relationship to vaccination of any solicited local or general symptoms | Within 7 days after each vaccine dose | ||
Secondary | Occurrence of serious adverse events | Up to one month after the last dose of vaccine | ||
Secondary | Occurrence, intensity and relationship to vaccination of any unsolicited symptom | Within 30 days after each vaccine dose | ||
Secondary | Occurrence of clinically relevant abnormalities in biochemical and hematological parameters | Assessed at Month 0, one month and six months after the last dose of vaccine | ||
Secondary | Occurrence of serious adverse events during the extended safety follow-up | Up to six months after the last dose of vaccine | ||
Secondary | Occurrence of pregnancy and pregnancy outcomes, new onset chronic diseases or medically significant conditions, regardless of causal relationship to vaccination | Throughout the study period (Month 0 up to six months after the last dose of vaccine) | ||
Secondary | HPV-16 and HPV-18 seropositivity rates and GMTs before the second dose of vaccine | One month after the second dose of vaccine, and six months after the last dose of vaccine | ||
Secondary | Seropositivity rates to other defined HPV types and GMTs before the second dose of vaccine | One month after the second dose of vaccine and at one month and six months after the last dose of vaccine | ||
Secondary | HPV-16 and -18 seropositivity rates and GMTs | One month after the last dose of vaccine |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01290393 -
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
|
||
Completed |
NCT00369824 -
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT00345878 -
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
|
Phase 3 | |
Completed |
NCT00947115 -
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT01187927 -
Drug Use Investigation for Cervarix®
|
N/A | |
Completed |
NCT00169494 -
Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18
|
Phase 3 | |
Completed |
NCT01190176 -
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
|
Phase 3 | |
Completed |
NCT00359619 -
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
|
Phase 2 | |
Completed |
NCT00196937 -
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
|
Phase 3 | |
Completed |
NCT00534638 -
Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
|
Phase 4 | |
Completed |
NCT00250276 -
Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.
|
Phase 3 | |
Completed |
NCT01031069 -
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
|
Phase 4 | |
Completed |
NCT00996125 -
Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects
|
Phase 3 | |
Completed |
NCT00779766 -
Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects
|
Phase 3 | |
Completed |
NCT01953822 -
Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom
|
N/A | |
Completed |
NCT01153906 -
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
|
N/A | |
Completed |
NCT01207999 -
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
|
N/A | |
Completed |
NCT00693615 -
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females
|
Phase 2 | |
Completed |
NCT00693966 -
Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females
|
Phase 2 | |
Completed |
NCT00541970 -
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
|
Phase 1 |